Bausch Health (BHC) is expected to post Q1 revenue of $2.24 billion, shy of the $2.29 billion estimate of analysts polled by FactSet, RBC Capital Markets said in an earnings preview Monday.
RBC analysts also said they expect the pharmaceutical company to report Q1 adjusted EBITDA of $720 million while analysts surveyed by FactSet expect $769.8 million.
The investment firm said it revised its Q1 estimates due to foreign exchange movements and updated prescription data. Regarding tariffs, RBC analysts said they plan to seek updated comments from management on the potential impact to the company. Previously, Bausch Health's management said they were forecasting an impact of less than $500 million to cash flow under a 25% tariff rate.
Bausch Health is due to report Q1 results after the close on April 30.
RBC cut its price target to $8.50 from $9 and kept a sector perform rating on the stock.
Price: 5.09, Change: -0.25, Percent Change: -4.60
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.